Evogene Ltd.

NasdaqCM:EVGN Stock Report

Market Cap: US$10.4m

Evogene Future Growth

Future criteria checks 2/6

Evogene is forecast to grow earnings and revenue by 34.3% and 37.6% per annum respectively.

Key information

34.3%

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth26.7%
Revenue growth rate37.6%
Future return on equityn/a
Analyst coverage

Low

Last updated29 Aug 2024

Recent future growth updates

Recent updates

Evogene unit files for EPA approval of bio-fungicide LAV.311 for fruit rots

Oct 12

Evogene unit launches 2nd-gen medical cannabis products in Israel

Sep 21

Lavie Bio appoints Guri Oron as CEO

Sep 14

Evogene GAAP EPS of -$0.42 misses by $0.23, revenue of $0.55M beats by $0.33M

Aug 31

Evogene regains compliance with Nasdaq's minimum bid price requirement

Aug 25

Evogen stock rises after unit gets $10M investment from ICL under collaboration agreement

Aug 17

Update On Evogene's Subsidiaries: Biomica, Lavie Bio And AgPlenus

Mar 22

Evogene: Computational Biology Technology Hub; Focus On Canonic (Medical Cannabis)

Mar 03

Evogene's Canonic Begins Selling High THC Cannabis In Israeli Medical Market

Sep 14

Evogene: Bullish With Canonic's Entry Into Israeli Medical Cannabis Markets

Jun 16

Evogene EPS beats by $0.01, beats on revenue

May 26

Evogene unit - Canonic inks cultivation deal for medical cannabis varieties

Dec 23

AgPlenus reaches a 'Lead' Stage in its mode-of-action herbicide program

Dec 15

Evogene: Q3 Update And Upcoming Catalysts

Nov 30

Earnings and Revenue Growth Forecasts

NasdaqCM:EVGN - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202640-12N/AN/A2
12/31/202520-20N/AN/A2
12/31/202415-19N/AN/A2
6/30/20249-20-20-20N/A
3/31/20249-21-20-19N/A
12/31/20236-24-22-22N/A
9/30/20236-20-19-18N/A
6/30/20232-23-22-21N/A
3/31/20232-25-23-22N/A
12/31/20222-27-25-24N/A
9/30/20221-31-31-30N/A
6/30/20221-32-29-28N/A
3/31/20221-29-29-28N/A
12/31/20211-28-26-25N/A
9/30/20211-29-24-24N/A
6/30/20211-26-23-22N/A
3/31/20211-24-19-19N/A
12/31/20201-23-20-20N/A
9/30/20201-21-18-17N/A
6/30/20201-21-18-17N/A
3/31/20200-21-19-18N/A
12/31/20191-18-19-18N/A
9/30/20191-18-16-16N/A
6/30/20192-18-16-16N/A
3/31/20192-19-16-16N/A
12/31/20182-21-16-15N/A
9/30/20182-21-16-16N/A
6/30/20182-21-16-15N/A
3/31/20183-21N/A-16N/A
12/31/20173-21N/A-16N/A
9/30/20174-21N/A-17N/A
6/30/20175-21N/A-16N/A
3/31/20175-21N/A-15N/A
12/31/20167-20N/A-12N/A
9/30/20168-18N/A-12N/A
6/30/20169-17N/A-11N/A
3/31/201610-17N/A-12N/A
12/31/201511-17N/A-12N/A
9/30/201512-17N/A-10N/A
6/30/201512-17N/A-9N/A
3/31/201513-16N/A-8N/A
12/31/201415-15N/A-9N/A
9/30/201417-14N/A-8N/A
6/30/201418-12N/A-7N/A
3/31/201418-11N/A-6N/A
12/31/201315-9N/A-5N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: EVGN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: EVGN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: EVGN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: EVGN's revenue (37.6% per year) is forecast to grow faster than the US market (8.9% per year).

High Growth Revenue: EVGN's revenue (37.6% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if EVGN's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y